Related references
Note: Only part of the references are listed.Targeted protein degraders crowd into the clinic
Asher Mullard
NATURE REVIEWS DRUG DISCOVERY (2021)
Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy
Xin Li et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
A Facile Synthesis of Ligands for the von Hippel-Lindau E3 Ligase
Christian Steinebach et al.
SYNTHESIS-STUTTGART (2020)
Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer
Xin Han et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
Sajid Khan et al.
NATURE MEDICINE (2019)
PROTACs: great opportunities for academia and industry
Xiuyun Sun et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
Demonstrating In-Cell Target Engagement Using a Pirin Protein Degradation Probe (CCT367766)
Nicola E. A. Chessum et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
Michael Zengerle et al.
ACS CHEMICAL BIOLOGY (2015)
Small-Molecule Inhibitors of the Interaction between the E3 Ligase VHL and HIF1a
Dennis L. Buckley et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2012)
Thalidomide metabolism and hydrolysis: Mechanisms and implications
Erin R. Leppert et al.
CURRENT DRUG METABOLISM (2006)
Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation
KM Sakamoto et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Share Paper
